---
$id: https://graph.org.ai/products/commodity/51183301
$type: Product
source: UNSPSC
code: "51183301"
title: "Linagliptin"
class: "51183300"
classTitle: "Antidiabetic and hyperglycemic dipeptidyl peptidase-4 inhibitors"
family: "51180000"
familyTitle: "Hormones and hormone antagonists"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Linagliptin

**UNSPSC Code**: 51183301
**Class**: [Antidiabetic and hyperglycemic dipeptidyl peptidase-4 inhibitors](Antidiabetic and hyperglycemic dipeptidyl peptidase-4 inhibitors.mdx)
**Family**: [Hormones and hormone antagonists](../Hormones and hormone antagonists.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X29ZEJ4R2. European Medicines Agency schedules Linagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31340. Linagliptin generally arises in the molecular formula C25H28N8O2. The term LINAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 1, 2009, list 61.) As of Q4 2014, LINAGLIPTIN remains US FDA's Preferred Term for this commodity. Linagliptin bears US NLM identifiers UMLS ID C2746078 and NCI Concept Code C83887. SMILES: CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.

